These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 19181468)

  • 41. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT scans for diagnosing ovarian cancer recurrence.
    Kitajima K; Ueno Y; Suzuki K; Kita M; Ebina Y; Yamada H; Senda M; Maeda T; Sugimura K
    Eur J Radiol; 2012 Nov; 81(11):3557-62. PubMed ID: 22534465
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients.
    Ohno Y; Nishio M; Koyama H; Yoshikawa T; Matsumoto S; Takenaka D; Seki S; Tsubakimoto M; Sugimura K
    Eur J Radiol; 2013 Nov; 82(11):2018-27. PubMed ID: 24012452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses.
    Drzezga A; Souvatzoglou M; Eiber M; Beer AJ; Fürst S; Martinez-Möller A; Nekolla SG; Ziegler S; Ganter C; Rummeny EJ; Schwaiger M
    J Nucl Med; 2012 Jun; 53(6):845-55. PubMed ID: 22534830
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT.
    Kitajima K; Yamamoto S; Fukushima K; Yamakado K; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Hirota S
    Eur J Radiol; 2016 Mar; 85(3):593-8. PubMed ID: 26860672
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.
    Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):480-6. PubMed ID: 17089122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer.
    Schmidt GP; Baur-Melnyk A; Haug A; Utzschneider S; Becker CR; Tiling R; Reiser MF; Hermann KA
    Eur Radiol; 2009 Jun; 19(6):1366-78. PubMed ID: 19190917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MRI and PET/CT of patients with bone metastases from breast carcinoma.
    Grankvist J; Fisker R; Iyer V; Fründ ET; Simonsen C; Christensen T; Stenbygaard L; Ewertz M; Larsson EM
    Eur J Radiol; 2012 Jan; 81(1):e13-8. PubMed ID: 21227614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
    Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recurrent colon cancer involving the urinary bladder identified with F-18 FDG PET/CT after forced diuresis.
    Chen CJ; Chao TB; Shih DF
    Clin Nucl Med; 2010 Apr; 35(4):258-9. PubMed ID: 20305415
    [No Abstract]   [Full Text] [Related]  

  • 50. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual-modality PET/CT instrumentation-today and tomorrow.
    Lonsdale MN; Beyer T
    Eur J Radiol; 2010 Mar; 73(3):452-60. PubMed ID: 20096520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system?
    Buchbender C; Hartung-Knemeyer V; Heusch P; Heusner TA; Beiderwellen K; Wittsack HJ; Kühl H; Forsting M; Bockisch A; Antoch G; Lanzman RS
    Eur J Radiol; 2013 Feb; 82(2):380-4. PubMed ID: 23238361
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of FDG PET/CT in staging of recurrent ovarian cancer.
    Son H; Khan SM; Rahaman J; Cameron KL; Prasad-Hayes M; Chuang L; Machac J; Heiba S; Kostakoglu L
    Radiographics; 2011; 31(2):569-83. PubMed ID: 21415197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?
    Zoller M; Kohlfuerst S; Igerc I; Kresnik E; Gallowitsch HJ; Gomez I; Lind P
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):487-95. PubMed ID: 17103166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.
    Kitajima K; Murakami K; Yamasaki E; Domeki Y; Kaji Y; Fukasawa I; Inaba N; Suganuma N; Sugimura K
    Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1439-48. PubMed ID: 18418592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDG-PET/CT in the diagnosis of recurrent breast cancer.
    Murakami R; Kumita S; Yoshida T; Ishihara K; Kiriyama T; Hakozaki K; Yanagihara K; Iida S; Tsuchiya S
    Acta Radiol; 2012 Feb; 53(1):12-6. PubMed ID: 22067206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: preliminary observations.
    Huellner MW; Appenzeller P; Kuhn FP; Husmann L; Pietsch CM; Burger IA; Porto M; Delso G; von Schulthess GK; Veit-Haibach P
    Radiology; 2014 Dec; 273(3):859-69. PubMed ID: 25102372
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative study of two whole-body imaging techniques in the case of melanoma metastases: advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT.
    Laurent V; Trausch G; Bruot O; Olivier P; Felblinger J; Régent D
    Eur J Radiol; 2010 Sep; 75(3):376-83. PubMed ID: 19497694
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancers of the oral cavity and oropharynx: FDG PET with contrast-enhanced CT in the posttreatment setting.
    King KG; Kositwattanarerk A; Genden E; Kao J; Som PM; Kostakoglu L
    Radiographics; 2011; 31(2):355-73. PubMed ID: 21415184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management.
    Piperkova E; Raphael B; Altinyay ME; Castellon I; Libes R; Sandella N; Heiba S; Abdel-Dayem H
    Clin Nucl Med; 2007 Jun; 32(6):429-34. PubMed ID: 17515747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.